Answers are grounded in this paper and cite their sources.
High co-resistance rates were observed for oral antibiotics among ESBL phenotypes raising concerns regarding empiric use of FQ and TMP-SMX for treating resistant UTIs outside of the hospital. In contrast, intravenous carbapenems retain activity against resistant UTI pathogens. New oral options with the spectrum of the carbapenems would address an unmet need for managing resistant UTIs.
No takes yet. Share an insight, caveat, or question.
Critchley et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: